Trials / Enrolling By Invitation
Enrolling By InvitationNCT07312136
MASLD in Type 2 Diabetes in Primary Care - a Follow-up Study
Evaluating the Prevalence and Severity of MASLD in Primary Care - a Follow-up Study
- Status
- Enrolling By Invitation
- Phase
- —
- Study type
- Observational
- Enrollment
- 317 (estimated)
- Sponsor
- Linkoeping University · Other Government
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The EPSOMIP2 (Evaluating the Prevalence and Severity Of MASLD In Primary care - a Follow-up Study) trial is a longitudinal cohort study of patients with type 2 diabetes recruited from primary health care centers in Östergötland, Sweden. Between 2019-2023, 317 patients were included and underwent rigorous clinical evaluation, vibration controlled transient elastography, biobanking of bloodsamples, and the latest magnetic resonance techniques to liver and body composition. All patients alive will be re-invited to undergo the same evaluation and additional tests.
Conditions
- MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease
- Cirrhosis
- Advanced Fibrosis
- Sarcopenia
- Obesity & Overweight
- Type 2 Diabetes
- Hypertension
- OSAS (Obstructive Sleep Apneas Syndrome)
- Metabolic Syndrome
Timeline
- Start date
- 2025-12-16
- Primary completion
- 2031-12-31
- Completion
- 2034-12-31
- First posted
- 2025-12-31
- Last updated
- 2025-12-31
Locations
1 site across 1 country: Sweden
Source: ClinicalTrials.gov record NCT07312136. Inclusion in this directory is not an endorsement.